Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLL – OncLive
OncLive |
Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLL
OncLive Treatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic … |
